RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients.
Springer Science and Business Media LLC
MetadataShow full item record
RA-MAP Consortium. (2022). RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients.. Sci Data https://doi.org/10.1038/s41597-022-01264-y
Rheumatoid arthritis (RA) is a chronic inflammatory disorder with poorly defined aetiology characterised by synovial inflammation with variable disease severity and drug responsiveness. To investigate the peripheral blood immune cell landscape of early, drug naive RA, we performed comprehensive clinical and molecular profiling of 267 RA patients and 52 healthy vaccine recipients for up to 18 months to establish a high quality sample biobank including plasma, serum, peripheral blood cells, urine, genomic DNA, RNA from whole blood, lymphocyte and monocyte subsets. We have performed extensive multi-omic immune phenotyping, including genomic, metabolomic, proteomic, transcriptomic and autoantibody profiling. We anticipate that these detailed clinical and molecular data will serve as a fundamental resource offering insights into immune-mediated disease pathogenesis, progression and therapeutic response, ultimately contributing to the development and application of targeted therapies for RA.
Arthritis, Rheumatoid, Autoantibodies, Biological Specimen Banks, Humans, Monocytes, Proteomics, Vaccines
Medical Research Council, 415 UK (An Immunological Toolkit for Clinical Application, grant number G1001518)
Medical Research Council (MR/L016311/1)
External DOI: https://doi.org/10.1038/s41597-022-01264-y
This record's URL: https://www.repository.cam.ac.uk/handle/1810/331006
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com